Mr. Glen Rehman reports

NEUTRISCI PROVIDES UPDATE ON PATENT PENDING TECHNOLOGY

NeutriSci International Inc. has made advancements with its patent-pending technology, trade named Cryolisation.

The Cryolisation process is used to prepare oral dosage forms comprising cannabinoid and stilbenoid compounds which improve the dissolution rate and bioavailability of cannabinoid compounds.

Preliminary research data indicate that cannabinoid and stilbenoid formulations prepared using the Cryolisation process increase absorption rates of cannabinoid compounds four to five times over consumption of cannabinoid compounds alone. The tested formulations appear to increase the amount of active ingredient the body can absorb while simultaneously increasing the rate of absorption with tetrohydrocannabinol and cannabidiol detected in the bloodstream of subjects within 10 minutes of initial consumption. NeutriSci's Cryolisation technology may provide an opportunity for manufacturers of cannabinoid-infused products to use less active ingredient while still achieving the desired results, thus lowering cost of manufacturing while increasing profits.

As previously announced, NeutriSci has filed a United States provisional patent application (United States provisional patent No. 62/628,735; Compositions Comprising Co-crystals of Stilbenoids and Cannabinoids) relating to compositions comprising pterostilbene and other stilbenoids in formulations which improve the dissolution rate and bioavailability of cannabinoid compounds.

NeutriSci's chief executive officer, Glen Rehman, stated: "We have spent a great deal of time and resources positioning ourselves to be ready for the international demand for Cryolisation technology. Producers and manufacturers from around the globe have been inquiring about possible partnership opportunities, due to the potential of the Cryolisation technology and the popularity of the form factor of our products currently in development."

We seek Safe Harbor.